19062-36-3

Upstream product

• 1028-39-3 3-(4-bromo-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 87551-35-7 sodium p-bromoanilinedithiocarbamate 
• 23121-37-1 methyl N-p-bromophenyldithiocarbamate 
• 1028-39-3 3-(4-bromophenyl)-2-thioxo-2,3-dihydroquinazoline-4(1H)-one 
• 106-40-1 4-bromo-aniline 
• 1985-12-2 4-Bromophenyl isothiocyanate 
• 118-92-3 anthranilic acid 

Downstream Products

• 77437-20-8 C₂₂H₁₈BrN₅OS 
• 77775-32-7 C₂₁H₁₆BrN₅O₂ 
• 67443-06-5 1-[3-(4-bromo-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-4-phenyl-thiosemicarbazide 
• 87465-29-0 2-{[3-(4-Bromo-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-hydrazono}-propionic acid 
• 85772-52-7 4-(4-Bromo-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazoline-1-carboxylic acid ethyl ester 
• 87009-89-0 3-(4-Bromo-phenyl)-2-{N'-[1-methyl-3-oxo-but-(Z)-ylidene]-hydrazino}-3H-quinazolin-4-one 
• 77747-38-7 C₂₅H₁₈BrN₅O₂ 
• 85772-49-2 1-Amino-4-(4-bromo-phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one 
• 132331-25-0 3-p-bromophenyl-2-<4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-hydrazono-3,5-dioxo-2H-pyrazolidin-1-yl>-4(3H)-quinazolinone 
• 77437-19-5 C₂₁H₁₅Br₂N₅OS 
• 77437-18-4 C₁₉H₂₀BrN₅OS 
• 85773-30-4 3-[4-(4-Bromo-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-1-yl]-propionic acid ethyl ester 
• 132331-22-7 3-p-bromophenyl-2-<4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-azo-3,5-dimethyl-1H-pyrazol-1-yl>-4(3H)-quinazolinone 
• 132331-18-1 3-p-bromophenyl-2-<4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)hydrazono-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl>-4(3H)-quinazolinone 

Relevant academic research and scientific papers

Identification of potent cholecystokinin-B receptor antagonists: Synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells

Advanced malignant stages of pancreatic cancer have poor prognosis and very few treatment strategies are available. Pancreatic cancer is known to possess unique growth-related receptors that when activated, stimulate tumour proliferation. Gastrin and its related peptide cholecystokinin (CCK) are also significantly involved in the growth of this cancer type as well as other malignancies through activation of the cholecystokinin-B receptor (CCK-BR). New treatment strategies with CCK-BR antagonists are being suggested that suppress the growth promoting effects of gastrin. In this paper, we report the development of two series of quinazolinone derivatives incorporating hydrazinecarbothioamide (compounds 3a-g) and the hydrazino group (compounds 4a-e) as linkers for developing CCK-BR antagonists. The affinities of the compounds were determined using docking into the CCK-BR homology modeled structure. The compounds were tested for in vitro CCK-BR binding and gastric acid secretion in an isolated lumen-perfused mouse stomach assay. The compounds exhibited CCK-BR binding activity (IC50) in the range of 0.2-975 nM and showed good gastric acid secretion inhibitory activity. Molecular modeling of the compounds was done and pharmacophore mapping results showed good prediction of in vitro activity which correlated well with the experimental antagonistic activity. The compounds were further tested for their cytotoxicity on CCK-BR expressing pancreatic cancer cells. The results of the study provided two potent CCK-BR antagonists which also possess good to moderate growth inhibitory activities against pancreatic cancer cells.

Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives

A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones (6a-x) with triazole and other heterocyclic substituents (7-14) were synthesized and the compounds were evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests. Among the compounds studied, 6o and 6q showed wide margins of safety with protective indices (PIs) that were much higher than those of currently used drugs (PI6o > 25.5, PI6q > 26.0). Compounds 6o and 6q showed significant oral activity against MES-induced seizures in mice, with ED50 values of 88.02 and 94.6 mg/kg, respectively. The two compounds were also found to have potent activity against seizures that were induced by pentylenetetrazole and bicuculline. A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones with triazole and other heterocyclic substituents were synthesized and the compounds were evaluated for their anticonvulsant activity and neurotoxicity using maximal electroshock and rotarod neurotoxicity tests.

Cynogen bromide and ethylacetoacetate in heterocyclization: Novel synthesis of tetracyclic derivative of 3-aryl quinazolinones

(Chemical Equation Presented) In this work, tricyclic 1-amino-4- (substituted phenyl)[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one 3 was synthesized by treatment of 2-hydrazinyl-3-(substituted phenyl)quinazolin-4(3H)-one 2 with cyanogen bromide, which on cyc